Abstract
Introduction: Multiple sclerosis is a chronic neurodegenerative and autoimmune disease of the central nervous system. In Colombia, is the most common rare-orphan disease, with 3,224 reported cases between 2016 and 2021. The treatment is based on a variety of disease-modifying therapies aimed atducing relapses, decreasing imaging activity, and delaying the progression of disability. However, clinical management presents challenges due to the lack of clear definitions of disease-modifying therapy failure and the absence of explicit guidelines for treatment changes.
Objective: Develop a definition of therapeutic failure and design an algorithm for management of therapeutic failure in patients with relapsing multiple sclerosis in Colombia
Materials and methods: An expert consensus was carried out using the Delphi methodology in two virtual rounds with 10 experts. A literature review was conducted to gather information for designing the definition and therapeutic failure algorithm.
Results: A definition of therapeutic failure was elaborated, including an introduction and the description of clinical variables used to determine if a patient is experiencing therapeutic failure. An algorithm was developed with a therapeutic optimization strategy considering the individual needs of each patient based on the previously designed definition.
Conclusions: A definition and a specific management algorithm for Colombia were developed based on evidence, clinical experience, and expert recommendations. These tools will improve decision-making, follow-up, and treatment efficiency and will be updated periodically to reflect scientific advances and best practices.
References
Yamout BI, Alroughani R. Multiple Sclerosis. Semin Neurol. 2018;38(2):212-25. https://doi.org/10.1055/s-0038-1649502
Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014;122:231-66. https://doi.org/10.1016/B978-0-444-52001-2.00010-8
Vermersch P, De Sèze J, Clavelou P, Durand-Dubief F, Maillart E, Mekies C, et al. Expert opinion: criteria for second-line treatment failure in patients with multiple sclerosis. Mult Scler Relat Disord. 2019;36:101406. https://doi.org/10.1016/j.msard.2019.101406
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648. https://doi.org/10.1177/17562864211039648
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-21. https://doi.org/10.1177/1352458520970841
Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol. 2016;172(1):3-13. https://doi.org/10.1016/j.neurol.2015.10.006
Caparó-Zamalloa C, Velásquez-Rimachi V, Mori N, Dueñas-Pacheco WI, Huerta-Rosario A, Farroñay-García C, et al. Clinical pathway for the diagnosis and management of patients with relapsing-remitting multiple sclerosis: a first proposal for the Peruvian population. Front Neurol. 2021;12:667398. https://doi.org/10.3389/fneur.2021.667398
Instituto Nacional de Salud. Comportamiento de la notificación al Sivigila de las enfermedades huérfanas-raras, Colombia, 2021 hasta semana epidemiológica 20 [internet]. Boletín Epidemiológico Semanal. [citado 2022 oct. 4]. Disponible en: http://www.ins.gov.co/buscador-eventos/BoletinEpidemiologico/2021_Boletin_epidemiologico_semana_24.pdf
Jiménez-Pérez CE, Zarco-Montero LA, Castañeda-Cardona C, Otálora Esteban M, Martínez A, Rosselli D. Estado actual de la esclerosis múltiple en Colombia. Acta Neurol Colomb. 2015;31(4):385-90. https://doi.org/10.22379/2422402256
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis. Neurology. 2014;83(3):278-86. https://doi.org/10.1212/WNL.0000000000000560
Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(pt. 7):1900-13. https://doi.org/10.1093/cerebro/awq076
Hosseiny M, Newsome SD, Yousem DM. Radiologically isolated syndrome: a review for neuroradiologists. AJNR Am J Neuroradiol. 2020;41(9):1542-9. https://doi.org/10.3174/ajnr.A6649
Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(11):1192-8. https://doi.org/10.1136/jnnp-2013-304951
Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(9):a028928. https://doi.org/10.1101/cshperspect.a028928
Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61(11):1528-32. https://doi.org/10.1212/01.wnl.0000096175.39831.21
Huang WJ, Chen WW, Zhang X. Multiple sclerosis: pathology, diagnosis and treatments. Exp Ther Med. 2017;13(6):3163-6. https://doi.org/10.3892/etm.2017.4410
Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3-4):132-41. https://doi.org/10.1159/000360528
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73. https://doi.org/10.1016/S1474-4422(17)30470-2
Lizak N, Lugaresi A, Alroughani R, Lechner-Scott J, Slee M, Havrdova E, et al. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(3):196-203. https://doi.org/10.1136/jnnp-2016-313976
Brieva L, Casanova Estruch B, García Merino JA, Meca-Lallana V, Río J, Rodríguez-Antigüedad A, et al. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Mult Scler Relat Disord. 2022;63:103805. https://doi.org/10.1016/j.msard.2022.103805
Piena MA, Schoeman O, Palace J, Duddy M, Harty GT, Wong SL. Modified Delphi study of decision-making around treatment sequencing in relapsing-remitting multiple sclerosis. Eur J Neurol. 2020;27(8):1530-6. https://doi.org/10.1111/ene.14267
de Borda PM. Memoire sur les elections au scrutin [internet]. Histoire de l'Académie Royale des Sciences. [citado 2023 febr. 27]. Disponible en: http://asklepios.chez.com/XIX/borda.htm
Bartosik-Psujek H, Kaczy?ski ?, Górecka M, Rolka M, Wójcik R, Zi?ba P, et al. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis. Mult Scler Relat Disord. 2021;49:102769. https://doi.org/10.1016/j.msard.2021.102769
Bose D, Ravi R, Maurya M, Pushparajan L, Konwar M. Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: a systematic review and network meta-analysis. Mult Scler Relat Disord. 2022;61:103760. https://doi.org/10.1016/j.msard.2022.103760
Huisman E, Papadimitropoulou K, Jarrett J, Bending M, Firth Z, Allen F, et al. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis. BMJ Open. 2017;7(3):e013430. https://doi.org/10.1136/bmjopen-2016-013430
Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol. 2020;267(12):3489-98. https://doi.org/10.1007/s00415-019-09395-w
Liu Z, Liao Q, Wen H, Zhang Y. Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Autoimmun Rev. 2021;20(6):102826. https://doi.org/10.1016/j.autrev.2021.102826
McCool R, Wilson K, Arber M, Fleetwood K, Toupin S, Thom H, et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:55-61. https://doi.org/10.1016/j.msard.2018.12.040
Asha MZI, Al-Asaad Y, Khalil SFH. The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: a network meta-analysis. IBRO Neurosci Rep. 2021;11:103-11. https://doi.org/10.1016/j.ibneur.2021.08.003
Lucchetta RC, Tonin FS, Borba HHL, Leonart LP, Ferreira VL, Bonetti AF, et al. Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. CNS Drugs. 2018;32(9):813-26. https://doi.org/10.1007/s40263-018-0541-5
Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255-74. https://doi.org/10.2217/cer-2020-0122
Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2018;34(8):1361-71. https://doi.org/10.1080/03007995.2017.1407303
Tjelle TE, Rose C, Ohm I, Pike E, Haheim L, Bidonde J, et al. [Disease modifying treatments for relapsing remitting multiple sclerosis, including rituximab. A health technology assessment]. Norwegian Institute of Public Health; 2019. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2019/disease-modifying-treatments-for-relapsing-remitting-multiple-sclerosis-including-rituximab-hta-rapport-2019.pdf
Xu X, Chi S, Wang Q, Li C, Xu B, Zhang J, et al. Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: a network meta-analysis. Mult Scler Relat Disord. 2018;25:322-8. https://doi.org/10.1016/j.msard.2018.08.026
Zhang J, Shi S, Zhang Y, Luo J, Xiao Y, Meng L, et al. Alemtuzumab versus interferon beta 1a for relapsing?remitting multiple sclerosis. Cochrane Database Syst Rev. 2017;11(11):CD010968. https://doi.org/10.1002/14651858.CD010968.pub2
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-34. https://doi.org/10.1056/NEJMoa1601277
Cree BAC, Pradhan A, Pei J, Williams MJ, OPERA I and OPERA II clinical investigators. Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Mult Scler Relat Disord. 2021;52:103010. https://doi.org/10.1016/j.msard.2021.103010
Ziemssen T, Medin J, Couto CAM, Mitchell CR. Multiple sclerosis in the real world: a systematic review of fingolimod as a case study. Autoimmun Rev. 2017;16(4):355-76. https://doi.org/10.1016/j.autrev.2017.02.007
Gärtner J, Chitnis T, Ghezzi A, Pohl D, Brück W, Häring DA, et al. Relapse rate and MRI activity in young adult patients with multiple sclerosis: a post hoc analysis of phase 3 fingolimod trials. Mult Scler J Exp Transl Clin. 2018;4(2):2055217318778610. https://doi.org/10.1177/2055217318778610
Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020;95(13):e1854-67. https://doi.org/10.1212/WNL.0000000000010376
Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, et al. Fingolimod vs dimethyl fumarate in multiple sclerosis: a real-world propensity score-matched study. Neurology. 2018;91(2):e153-61. https://doi.org/10.1212/WNL.0000000000005772
Skromme-Eisenberg E, Treviño-Frenk I, Llamosa García Velázquez GL, Quiñones-Aguilar S, Rivas-Alonso V, de la Maza-Flores M, et al. Clinical practice patterns in multiple sclerosis management: Mexican consensus recommendations. Mult Scler Relat Disord. 2021;53:103053. https://doi.org/10.1016/j.msard.2021.103053
Alroughani R, Inshasi J, Al-Asmi A, Alqallaf A, Al Salti A, Shatila A, et al. Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. Postgrad Med. 2020;132(4):368-76. https://doi.org/10.1080/00325481.2020.1734394
Alroughani R, Ashkanani A, Al-Hashel J, Khan R, Thussu A, Alexander KJ, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis in Kuwait. Clin Neurol Neurosurg. 2016;143:51-64. https://doi.org/10.1016/j.clineuro.2016.02.001
Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, et al. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol. 2006;13(1):61-71. https://doi.org/10.1111/j.1468-1331.2006.01147.x
Bigaut K, Cohen M, Durand-Dubief F, Maillart E, Planque E, Zephir H, et al. How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). Mult Scler Relat Disord. 2021;53:103076. https://doi.org/10.1016/j.msard.2021.103076
Finkelsztejn A, Gabbai AA, Fragoso YD, Carrá A, Macías-Islas MA, Arcega-Revilla R, et al. Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents. Arq Neuropsiquiatr. 2012;70(10):799-806. https://doi.org/10.1590/s0004-282x2012001000009
Cuevas C, Velázquez Quintana M, Núñez L, Skromme E, Árcega R, Barroso N, et al. Consenso Mexicano para la Esclerosis Múltiple. Guía diagnóstica y terapéutica. Rev Mex Neurosci. 2007;8(2):155-162. https://previous.revmexneurociencia.com/wp-content/uploads/2014/06/Nm072-09.pdf
Centro Nacional de Excelencia Tecnológica en Salud. Tratamiento modificador de enfermedad en pacientes con diagnóstico de esclerosis múltiple [internet]. Consejo de Salubridad General. [citado 2022 nov. 22]. Disponible en: http://www.facmed.unam.mx/sg/css/GPC/SIDSS-GPC/gpc/docs/SSA-417-10-ER.pdf
Fazekas F, Bajenaru O, Berger T, Fabjan TH, Ledinek AH, Jakab G, et al. How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol. 2013;4:10. https://doi.org/10.3389/fneur.2013.00010
Yamout B, Sahraian M, Bohlega S, Al-Jumah M, Goueider R, Dahdaleh M, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord. 2020;37:101459. https://doi.org/10.1016/j.msard.2019.101459
Yamout B, Alroughani R, Al-Jumah M, Goueider R, Dahdaleh M, Inshasi J, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). Curr Med Res Opin. 2015;31(7):1349-61. https://doi.org/10.1185/03007995.2015.1047750
NHS England. Treatment algorithm for multiple sclerosis disease-modifying therapies [internet]. NHS England [citado 2022 nov. 23]. Disponible en: https://www.england.nhs.uk/wp-content/uploads/2024/03/treatment-algorithm-for-multiple-sclerosis-disease-modifying-therapies-july-23.pdf
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96-120. https://doi.org/10.1177/1352458517751049
Cristiano E, Alonso R, Alvez Pinheiro A, Bacile EA, Balbuena ME, Ballario C, et al. Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients. J Neurol Sci. 2018;385:217-24. https://doi.org/10.1016/j.jns.2018.01.004
Vizcarra DR, Cruz AG, Rojas E, Mori N, Caparó C, Castañeda CC, et al. Guía de práctica clínica para el diagnóstico y tratamiento de esclerosis múltiple en adultos. Rev Neuropsiquiatr. 2019;82(4):242-57. https://doi.org/10.20453/rnp.v82i4.3646
Correale J, Abad P, Alvarenga R, Alves-Leon S, Armas E, Barahona J, et al. Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization. J Neurol Sci. 2014;339(1-2):196-206. https://doi.org/10.1016/j.jns.2014.02.017
Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, et al. Treatment optimization in multiple sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci. 2020;47(4):437-55. https://doi.org/10.1017/cjn.2020.66
Ontaneda D, Tallantyre EC, Raza PC, Planchon SM, Nakamura K, Miller D, et al. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemp Clin Trials. 2020;95:106009. https://doi.org/10.1016/j.cct.2020.106009
Yamout B, Al-Jumah M, Sahraian MA, Almalik Y, Khaburi JA, Shalaby N, et al. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines. Mult Scler Relat Disord. 2024;83:105435. https://doi.org/10.1016/j.msard.2024.105435
Guo J, Wu J, Wang L, Liu H, Wu X, Yang H, et al. Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China. Ther Adv Neurol Disord. 2024;17:17562864241239117. https://doi.org/10.1177/17562864241239117
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.